We reviewed the drug treatment of @entity101 in the light of recent trials. beta-Blockers and diuretics clearly reduce mortality, @entity64 , and @entity301 ( @entity301 ) in @entity101 . Recent trials assessed whether newer agents that block the renin-angiotensin- @entity1369 system, or @entity460 blockers, offer any additional advantage, or have benefits in high-risk individuals with conventionally 'normal' blood pressure. The recent ALLHAT study claimed no differences in @entity301 or mortality when @entity9804 , @entity3591 , and @entity3593 were compared. However, the decrease in blood pressure was not the same with the three agents, and a substantial proportion of @entity1 enrolled did not have clinical disease. In contrast, the LIFE study (comparing @entity9886 and a beta-blocker) and the ANBP-2 study [comparing @entity1289 ( @entity1289 ) inhibition and a diuretic] reduced blood pressure similarly, yet demonstrated benefits in favour of @entity7743 blockers (ARBs) and @entity1289 inhibitors. Other trials indicated similar advantages of @entity1289 inhibitors or ARBs in @entity1 with @entity2316 . Among high-risk @entity1 with initial blood pressure in the 'normal' range, @entity1289 inhibitors significantly reduce clinical events (mortality, @entity64 , and @entity583 ), despite modest decreases in blood pressure, suggesting that additional mechanisms are responsible. Recent results of the Prospective Studies Collaboration show lower risk, even in the normal blood pressure range; high-risk @entity1 will benefit further from @entity1289 inhibitors and ARBs (and beta-blockers after @entity583 ). Data for other blood pressure decreasing agents are unavailable in such populations. We conclude that blood pressure decreasing per se is of clinical benefit, but drugs that block the renin-angiotensin system offer additional advantages. Drug choice is best determined by the @entity1 's clinical condition.

New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes'] @entity1369 :: ('MESH:D000450', 'Chemical') :: ['aldosterone'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity1289 :: ('1636', 'Gene') :: ['ACE', 'angiotensin-converting enzyme'] @entity301 :: ('MESH:D003327', 'Disease') :: ['CHD', 'coronary heart disease'] @entity2316 :: ('MESH:D003928', 'Disease') :: ['diabetic nephropathy'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity9886 :: ('MESH:D019808', 'Chemical') :: ['losartan'] @entity3591 :: ('MESH:D017311', 'Chemical') :: ['amlodipine'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity3593 :: ('MESH:D017706', 'Chemical') :: ['lisinopril'] @entity9804 :: ('MESH:D002752', 'Chemical') :: ['chlorthalidone'] @entity7743 :: ('185', 'Gene') :: ['angiotensin II type 1 receptor']
@entity101 :: (MESH:D006973,Disease) :: ['hypertension']
